A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
=== EC 1.8.7 With an iron–sulfur protein as acceptor === EC 1.8.7.1: assimilatory sulfite reductase (ferredoxin) EC 1.8.7.2: ferredoxin:thioredoxin reductase EC 1.8.7.3: ferredoxin:CoB-CoM heterodisulfide reductase
== Resources == Casss Times Archived 2006-09-28 at the Wayback Machine, Spring 2005 Casss Times Archived 2006-09-28 at the Wayback Machine, Autumn 2005 California Death Index Robert G Brownlee Marine project Archived 2014-04-15 at the Wayback Machine Article in The Scientist, June 1990 Applied Biosystems Timeline
Number average molar mass (Mn), also loosely referred to as number average molecular weight (NAMW). Mass average molar mass (Mw), where w stands for weight; also commonly referred to as weight average or weight average molecular weight (WAMW). Z-average molar mass (Mz), where z stands for centrifugation (from German Zentrifuge). Viscosity average molar mass (Mv).
=== Non-medical use === Vosilasarm and other SARMs are sold on the black market on the Internet. Aside from vosilasarm, the other most commonly used SARMs include enobosarm (ostarine; GTx-024, S-22), LGD-4033 (VK5211; "ligandrol"), and andarine (GTx-007; S-4). Social media has played an important role in facilitating the widespread non-medical use of SARMs.
Sources: en.wikipedia.org
Insulin degludec is an ultralong-acting basal insulin analogue developed by Novo Nordisk. Ultralong-acting insulins are a kind of insulin that can work up to a week. It is administered through subcutaneous injection to assist in controlling blood sugar levels in individuals with diabetes. Its duration of action lasts up to 42 hours, which is significantly longer than other long-acting insulins, such as insulin glargine and insulin detemir, which typically last 18 to 26 hours. This makes insulin degludec a once-daily basal insulin, providing a steady insulin level, in contrast to fast-acting bolus insulins. Insulin degludec is a modified form of insulin in which a single amino acid is deleted compared to human insulin. It is also conjugated to hexadecanedioic acid via a gamma-L-glutamyl spacer at the amino acid lysine at position B29. It is included on the World Health Organization's List of Essential Medicines as an alternative to insulin glargine. In 2022, it was the 138th most commonly prescribed medication in the United States, with more than 4 million prescriptions. Insulin Degludec is currently only produced by Novo Nordisk under the name Tresiba. It is also available under a generic label until the start of 2026.
Henan Corps Hubei Corps Hunan Corps Inner Mongolia Corps Jiangsu Corps Jiangxi Corps Jilin Corps Liaoning Corps Ningxia Corps Qinghai Corps Two mobile detachments Shaanxi Corps Shanxi Corps Shandong Corps Shanghai Corps Two mobile detachments
In one study, disk diffusion method proved concentration-dependent antifungal activity against Trichophyton, Microsporum and Epidermophyton, three of the most common species of dermatophytes that cause superficial fungal infections of human skin. Further research is needed, however, to examine the role of sangre de grado from Croton lechleri as an effective antifungal agent in animal and human models. Antiviral activity against influenza, parainfluenza, Herpes simplex viruses I and II, and Hepatitis A and B by Croton lechleri extracts and compounds have been exhibited. The most notable compound involved in antiviral activity is SP-303, also known as crofelemer, which has been heavily studied in vitro for its antiviral activity against the aforementioned viruses, as well as thymidine kinase mutants of HSV-1 and HSV-2 and acyclovir-resistant strains. Antidiarrhoeal Activity Crofelemer, a purified proanthocyanidin oligomer extracted from the sap of Croton lechleri has been investigated for potential antidiarrhoeal activity. Various clinical studies have confirmed significant improvement in acute E. coli and V. cholera diarrhea cases from the administration of crofelemer. In the context of the principal luminal membrane determinants of intestinal fluid secretion, the mechanism of crofelemer action involves the inhibition of apical membrane cAMP-stimulated (CFTR) and calcium-stimulated (CaCC) Cl− channels by crofelemer molecules, with little effect on cation channels or cAMP/calcium signaling.
Sources: en.wikipedia.org
=== Benefits to females === Among numerous species in the animal kingdom, females may benefit from absorbing nutrients and proteins from seminal fluid for food, antiviral and antibacterial properties, and enhanced fertilisation. In humans, seminal fluid provides anti-viral activity towards herpes simplex virus and can transfer anti-microbial peptides cathelicidin and lactoferrin. In birds and mammals, mutualistic bacteria such as Lactobacillus have been detected in fluid transferral. A study on the effect of semen in male-to-female transmission of HIV, in both humans and non-human primates (rhesus macaques), noted that regular intravaginal exposure to a healthy male's semen modulates the microenvironment in the female reproductive tract (FRT), and, paradoxically, improves the resistance in females against acquiring HIV by activating their bodies' anti-HIV mechanisms.
== External links == "The Cheminformatics and QSAR Society". Retrieved 2009-05-11. "The 3D QSAR Server". Retrieved 2011-06-18. Verma, Rajeshwar P.; Hansch, Corwin (2007). "Nature Protocols: Development of QSAR models using C-QSAR program". Protocol Exchange. doi:10.1038/nprot.2007.125. Archived from the original on 2007-05-01. Retrieved 2009-05-11. A regression program that has dual databases of over 21,000 QSAR models "QSAR World". Archived from the original on 2009-04-25. Retrieved 2009-05-11. A comprehensive web resource for QSAR modelers Chemoinformatics Tools Archived 2017-07-04 at the Wayback Machine, Drug Theoretics and Cheminformatics Laboratory Multiscale Conceptual Model Figures for QSARs in Biological and Environmental Science
=== Ribo-X === In 2007, the group of Jason W. Chin presented an orthogonal ribosome, which was optimized for Amber codon suppression. The 16S rRNA was mutated in such a way that it bound the release factor RF1 less strongly than the natural ribosome does. This ribosome did not eliminate the problem of lowered cell fitness caused by suppressed stop codons in natural proteins. However through the improved specificity it raised the yields of correctly synthesized target protein significantly (from ~20% to >60% percent for one amber codon to be suppressed and from <1% to >20% for two amber codons).
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.